Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of

Last Updated:
In the Matter of Watson Pharmaceuticals, Inc., a corporation and Andrx Corporation, a corporation.
FTC Matter/File Number:


Docket Number:


Enforcement Type:

Part 2 Consents

Case Summary

A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.

There is a related federal proceeding and two related administrative proceedings: